Abstract

COMBINATION AND RESISTANCE THERAPY IN LUNG CANCER

*Akansha Doifode, Komal Jaiswal, Dr. Sunil Jaybhaye, Ashwini Shelke, Sandip Phoke

ABSTRACT

Lung cancer is one of the leading causes of cancer-related deaths worldwide with a 5-year survival rate of less than 18%. One of the most prevalent cancers in the US is lung cancer. It is of the most avoidable as well. As with all diseases, early detection of lung cancer offers the best chance of a cure. However, a large number of lung cancer patients receive a diagnosis at an advanced stage, which is typically incurable. Chemotherapy and radiation therapy are important treatments for these patients. Recently, a number of antineoplastic drugs have emerged that hold greater promise for treating individuals with advanced lung cancer than they did in the past. This article examines lung cancer's prevalence, risk factors, pathogenesis, diagnosis, and treatment. Current treatment modalities include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy., Despite advances in therapeutic options, resistance to therapy remains a major obstacle to the obstacle to the effectiveness of long-term treatment, eventually leading to therapeutic insensitivity, poor progression-free survival and disease relapse. Resistance mechanisms stem from genetic mutations and/or epigenetic changes, unregulated drug efflux, tumor hypoxia, alterations in the tumor microenvironment, and several other cellular and molecular alterations.

Keywords: This article examines lung cancer's prevalence, risk factors, pathogenesis, diagnosis, and treatment.